Compass Course: Efficacy Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Golden Valley, Minnesota, United States, 55422
- Courage Kenny Rehabilitation Institute
-
Minneapolis, Minnesota, United States, 55407
- Abbott Northwestern Hospital
-
Shoreview, Minnesota, United States, 55126
- Allina Health Shoreview Clinic
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- 25 years of age or older
- Completed treatment (such as chemotherapy, radiation, surgery) for Stage 0, 1, 2, or 3 breast cancer at least 2 months prior to participating in the Compass Course intervention
- English speaking
- High school diploma or GED
- Able to see, hear, speak (with or without assistive devices)
- Able to provide own transportation to sessions
- Willing and able to commit to attend all 8 intervention sessions
Exclusion criteria (all self-reported):
- Stage 4 breast cancer or any other stage 4 cancer
- Actively receiving chemotherapy or radiation treatments for cancer. (However, patients may be on Herceptin and/or endocrine treatment and participate in the study.)
- History of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning
- Any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Spring 2018 Compass Course Group
Two groups of up to 15 participants (30 total) will receive the study intervention during Spring 2018.
All participants will complete study questionnaires before and after the Spring sessions.
|
An 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions.
The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention, called the Compass Course is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in their daily lives.
|
|
No Intervention: Spring 2018 Comparison Group
Two groups of up to 15 participants will receive the study intervention in Fall 2018.
All participants will complete study questionnaires before and after the Spring sessions.
Those who enroll in the study and agree to participate in the Fall sessions will serve as a no-treatment comparison group.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in psychological well-being
Time Frame: Will be administered at Week 0 (pre-testing), at Week 12 (session 8), and at 3 month follow up
|
Using the Psychological Scales of Wellbeing questionnaire (Ryff, 1989; Ryff, & Keyes, 1995), psychological wellbeing pre- and post- intervention will be tracked.
|
Will be administered at Week 0 (pre-testing), at Week 12 (session 8), and at 3 month follow up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment
Time Frame: Up to 1 month after IRB approval
|
Number of prospective participants approached by clinicians and number of self-referred prospective participants who contact PI or Study Coordinator with inquiries about the study
|
Up to 1 month after IRB approval
|
|
Time of pre-testing session
Time Frame: Duration of pre-testing session (approximately 2 hours) at week 0 to week 1
|
Actual length (in minutes) of pre-testing session.
|
Duration of pre-testing session (approximately 2 hours) at week 0 to week 1
|
|
Homework completion
Time Frame: Each week from week 2 through week 8
|
Whether or not homework was attempted
|
Each week from week 2 through week 8
|
|
Intervention fidelity
Time Frame: Each week from week 2 through week 8
|
Which key intervention elements were provided during a given session
|
Each week from week 2 through week 8
|
|
Engagement in Meaningful Activities
Time Frame: At week 0 and at week 12
|
Engagement in Meaningful Activities Survey (Eakman, 2010):A 12-item self-report questionnaire designed to measure the extent to which a person experiences meaningfulness in his/her daily life activities.
|
At week 0 and at week 12
|
|
Time of testing session
Time Frame: Each week from week 2 through week 8, approximately 2 hours at each session
|
Actual length (in minutes) of testing session.
|
Each week from week 2 through week 8, approximately 2 hours at each session
|
|
Time of post-testing session
Time Frame: Duration of session 8 (at week 12), approximately 1 hour
|
Actual length (in minutes) of testing session.
|
Duration of session 8 (at week 12), approximately 1 hour
|
|
Change in Meaning in life
Time Frame: At week 0 and at week 12, and at 3 month follow up
|
Meaning in Life Questionnaire (Steger et al., 2006): A 10-item questionnaire designed to measure 2 dimensions of meaning in life: Presence of Meaning (how much respondents feel their lives have meaning) and Search for Meaning (how much respondents strive to find meaning and understanding in their lives).
|
At week 0 and at week 12, and at 3 month follow up
|
|
Purpose Status and Expectations
Time Frame: At week 0, at week 12, and at 3 month follow up
|
A 2-question self-report developed by the study team to better understand what participants' hope to gain during the study and perceived changes.
|
At week 0, at week 12, and at 3 month follow up
|
|
Participant Experience of Compass Course
Time Frame: At week 12 and at week 14-20
|
Participant experience of Compass Course as measured by self-report questionnaire and post-intervention focus group.
|
At week 12 and at week 14-20
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- CKMW-1801
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
NCT05020860RecruitingBreast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer
-
NCT02580448CompletedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Male Breast Cancer | ER+ Breast Cancer | Cancer of the Breast
-
NCT00003199CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer
-
NCT01372579UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer
-
NCT01881048CompletedStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer
-
NCT01151449TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer
-
NCT01632332CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer
-
NCT02315196Active, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer
-
NCT01222377TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
NCT07214883RecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer Awareness
Clinical Trials on Compass Course
-
NCT05780658Completed
-
NCT04767464CompletedBreast Cancer | Breast Neoplasm
-
NCT02384642CompletedDomestic Violence | Sexual Assault | Interpersonal Relations | Marital Status
-
NCT01816061CompletedTraumatic Brain Injury | Post-Traumatic Stress Disorder
-
NCT06222359Not yet recruitingDepression | Multiple Sclerosis | Anxiety
-
NCT05140551CompletedDepression | Quality of Life | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes | Diabetes Mellitus, Type 1 | Anxiety | Loneliness | Distress, Emotional | Diabetes Distress
-
NCT06849869Recruiting
-
NCT05330299RecruitingPsychological Distress | IBD | Treatment of Illness-related Distress in IBD